Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCNASDAQ:BYSIOTCMKTS:EMISNASDAQ:FLXNNASDAQ:XENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ABYSIBeyondSpring$2.29+8.5%$2.37$0.65▼$4.00$82.13M0.15105,793 shs112,151 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AXENEXenon Pharmaceuticals$41.09+2.7%$44.47$27.99▼$50.99$3.02B1.15303,967 shs323,512 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%BYSIBeyondSpring+8.53%+27.22%-26.60%+154.44%+136.08%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals+2.70%-0.96%-6.61%-6.68%+4.66%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpring0.0041 of 5 stars0.00.00.00.00.02.50.0EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals1.7402 of 5 stars3.52.00.00.02.22.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/ABYSIBeyondSpringN/AN/A$1.25-45.41% DownsideEMISEmisphere TechnologiesN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AXENEXenon Pharmaceuticals3.00Buy$59.4444.67% UpsideCurrent Analyst RatingsLatest BSTC, FLXN, XENE, BYSI, and EMIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$62.004/10/2024XENEXenon PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.003/1/2024XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.003/1/2024XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.003/1/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $62.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81BYSIBeyondSpring$1.35M66.02N/AN/A($0.36) per share-6.36EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82XENEXenon Pharmaceuticals$9.43M328.68N/AN/A$14.18 per share2.90Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ABYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AXENEXenon Pharmaceuticals-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)Latest BSTC, FLXN, XENE, BYSI, and EMIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023XENEXenon Pharmaceuticals-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24BYSIBeyondSpringN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05XENEXenon PharmaceuticalsN/A23.6523.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%BYSIBeyondSpring40.29%EMISEmisphere TechnologiesN/AFLXNFlexion Therapeutics90.01%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%BYSIBeyondSpring29.31%EMISEmisphere Technologies72.90%FLXNFlexion Therapeutics9.13%XENEXenon Pharmaceuticals5.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableXENEXenon Pharmaceuticals25175.43 million71.34 millionOptionableBSTC, FLXN, XENE, BYSI, and EMIS HeadlinesSourceHeadlineFederated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 23 at 5:35 AMInvestors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)americanbankingnews.com - April 18 at 3:04 AMXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 16 at 8:30 AMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analystsamericanbankingnews.com - April 16 at 2:34 AMXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - April 14 at 3:36 AMNeedham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)marketbeat.com - April 12 at 8:14 AMXenon Pharmaceuticals Inc (XENE)investing.com - April 10 at 12:10 PMXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferenceglobenewswire.com - April 10 at 8:30 AMXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 4:01 PMSG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 2 at 4:18 AMAssenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 1 at 4:43 AMXenon Pharmaceuticals Incmoney.usnews.com - March 21 at 10:13 AMXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - March 19 at 8:26 AMXENE Apr 2024 47.500 putfinance.yahoo.com - March 16 at 1:48 PMXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 12 at 4:01 PMInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stockinsidertrades.com - March 11 at 6:41 AMInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...finance.yahoo.com - March 9 at 12:06 AMXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 5 at 4:01 PMBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progressmarkets.businessinsider.com - March 5 at 10:33 AMXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 2:52 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:52 AMXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 1 at 2:30 PMXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focuszacks.com - March 1 at 9:36 AMBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neurosciencemarkets.businessinsider.com - March 1 at 9:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.BeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Xenon PharmaceuticalsNASDAQ:XENEXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.